BIVIMEDIUM SIGNALFINANCIAL10-K

BIVI significantly reduced operating losses and liabilities while adding Long COVID as a new therapeutic target, though cash position declined substantially.

The company has dramatically improved its financial position with a 45% reduction in net losses and 74% decrease in total liabilities, suggesting better cost management and debt reduction. However, the 26% decline in cash reserves to $17.5M raises questions about runway duration despite the improved burn rate.

Comparing 2025-08-15 vs 2024-09-30View on EDGAR →
FINANCIAL ANALYSIS

BIVI showed significant operational improvement with R&D expenses falling 60% and net losses declining 45%, while simultaneously reducing total liabilities by 74% and improving stockholders' equity by 23%. Despite these positive trends, cash declined substantially by $6.3M to $17.5M, though the improved operating cash flow burn rate suggests better capital efficiency. The overall picture indicates a company that has successfully reduced costs and debt burden but needs to monitor cash runway carefully.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
-75.7%
$9.4M$2.3M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-73.7%
$9.7M$2.6M

Liabilities reduced 73.7% — deleveraging improves balance sheet strength and financial flexibility.

R&D Expense
P&L
-59.9%
$23.1M$9.3M

R&D spending cut 59.9% — could signal cost discipline or concerning reduction in innovation investment.

Net Income
P&L
+45.4%
-$32.1M-$17.5M

Net income grew 45.4% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+43.9%
-$32.2M-$18.1M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Interest Expense
P&L
-32.7%
$4.3M$2.9M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Operating Cash Flow
Cash Flow
+31.9%
-$27.9M-$19.0M

Operating cash flow surged 31.9% — exceptional cash generation, highest quality earnings signal.

Cash & Equivalents
Balance Sheet
-26.4%
$23.8M$17.5M

Cash decreased 26.4% — monitor burn rate and upcoming capital needs.

Stockholders Equity
Balance Sheet
+22.6%
$15.5M$19.0M

Equity base grew 22.6% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
-14.5%
$25.2M$21.6M

Total assets contracted 14.5% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2025-08-15
PRIOR — 2024-09-30
ADDED
There were 7,534,225 shares of the Registrant s Class A Common Stock, $0.0001 par value per share, outstanding as of August 15, 2025.
( NeurMedix ) a privately held clinical-stage pharmaceutical company and a related party in June 2021.
Bezisterim, the approved generic name for NE3107 is an investigational, novel, orally administered small molecule that is thought to inhibit inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action.
Food and Drug Administration ( FDA ), represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering from AD , 1 million Americans suffering from PD and Long COVID affects approximately 20 million adults in the US, and millions more worldwide.
In neurodegenerative disease, the Company s drug candidate bezisterim is an orally bioavailable, Blood Brain Barrier ( BBB )-permeable, and anti-inflammatory agent that is an insulin-sensitizer.
+7 more — sign up free →
REMOVED
All statements other than statements of historical fact are statements that could be deemed forward-looking statements.
The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
( NeurMedix ) a privately held clinical-stage pharmaceutical company and a related party in June 2021 .
In April 2024, the Company announced that the United States Adopted Names Council, and the World Health Organization International Nonproprietary Names expert committee had approved bezisterim as the non-proprietary (generic) name for NE3107.
Bezisterim (NE3107) is an investigational, novel, orally administered small molecule that is thought to inhibit inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →